Rich Heyman, Metacrine chairman (ARCH)
A Rich Heyman biotech backed by a top Salk scientist is auctioned off for its dwindling cash reserves
It’s time to turn off the lights at Metacrine. The party ended months ago.
The Rich Heyman startup $MTCR came out of the IPO gate in the fall of 2020 with high hopes, a top scientist in the founders circle and a well-connected board of directors in pursuit of one of the hottest targets in drug development. But just a year later its great expectations in NASH had foundered, its stock was in a tailspin and the staff roster was cut to the bone.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
